Medical Device Economic Operator Duties Compared: EU MDR, NZ, Singapore, Canada, SFDA

Who Is Responsible When the Device Reaches the Border? It Depends on the Country

A medical device's path from factory to patient runs through a chain of "economic operators" — the manufacturer, the authorized representative, the importer, and the distributor. Each market assigns these roles different legal duties, and getting the role wrong is one of the most common causes of held shipments, refused registrations, and post-market liability.

Five regimes are worth comparing side by side because they sit at very different points on the oversight spectrum: the EU MDR (Articles 11–16), the strictest with prescriptive verification duties; New Zealand's WAND sponsor system, the lightest with notification-only oversight; Singapore's Health Products Act dealer licensing; Canada's MDEL regime; and Saudi Arabia's SFDA MDS-REQ 9 establishment licensing. This is regulatory research for supply-chain planning — not legal advice for a specific distribution arrangement.

Side-by-Side: The Economic-Operator Roles

EU MDR: The Verification-Heavy Model

The EU MDR is the most prescriptive. Four roles are defined as "economic operators," each with article-level duties:

Authorized Representative (Article 11): designated by a manufacturer outside the EU; performs mandated tasks and is jointly and severally liable for defective devices alongside the manufacturer.

Importer (Article 13): before placing a device on the market, the importer must verify that:

• the device is CE marked and an EU Declaration of Conformity has been drawn up (13(2)(a));
• the manufacturer is identified and an AR has been designated (13(2)(b));
• the device is labelled and accompanied by the required IFU (13(2)(c));
• a UDI has been assigned where applicable (13(2)(d)).

The importer must then indicate its own name/address on the device or packaging (13(3)), verify EUDAMED registration and add its own details (13(4)), ensure storage/transport conditions (13(5)), keep a register of complaints, non-conforming devices, recalls and withdrawals (13(6)), and inform the manufacturer — and competent authorities if there is a serious risk — of non-conformity (13(7)).

Distributor (Article 14): a lighter set — verify CE marking, IFU, manufacturer/AR identification; the distributor may use a sampling method representative of devices supplied (unlike the importer's per-shipment verification), and must cooperate on complaint handling, post-market surveillance, and vigilance.

Article 16 trap: if a distributor or importer makes any modification to the device (including its intended purpose) that affects conformity, it becomes the manufacturer and inherits all manufacturer obligations (QMS, technical documentation, CE marking in its own name). The same entity cannot be both importer and distributor for the same device — but the same entity can combine the Authorized Representative and importer roles (per the MDCG 2021-27 Q&A), which is a common commercial setup.

New Zealand: WAND and the Sponsor

New Zealand is the opposite philosophy: no pre-market approval, no conformity assessment, no fee. Oversight runs through the WAND (Web-Assisted Notification of Devices) database under the Medicines (Database of Medical Devices) Regulations 2003.

• Sponsor = the legally responsible entity. A sponsor is any importer, exporter, or manufacturer located and operating a business in New Zealand. Foreign manufacturers must appoint a New Zealand-based sponsor.
• Notification, not approval: the sponsor must notify a device in WAND within 30 working days of becoming the sponsor, and update within 10 days of changes. Schedule 1 of the Regulations lists exempt devices.
• What the sponsor actually owes: compliance with the Medicines Act 1981, Medicines Regulations 1984, and the MD Regulations 2003 — correct risk classification, correct labelling and advertising, adverse-event reporting, and initiating recalls. The sponsor must be able to produce evidence of safety/performance (CE, FDA, Health Canada, TGA, or Japan approvals are accepted as reference-country evidence).
• Enforcement: contravening certain notification regulations is an offence punishable by a fine up to NZ$500 (Reg. 14) — light in dollar terms, but the real exposure is the recall and adverse-event obligations, which carry their own weight.

Cross-market trap: New Zealand's sponsor model looks easy, but because there is no conformity assessment, the sponsor carries the substantive safety responsibility with minimal regulator screening — so the quality of the reference-country dossier is the entire safety net.

Singapore: Dealer Licensing Under the Health Products Act

Singapore splits oversight into dealer licensing (entity-level) and product registration (device-level), both under the Health Products Act 2007 and Health Products (Medical Devices) Regulations 2010.

• "Dealer" = manufacturer, importer, or wholesaler. Each needs a Dealer's Licence (Manufacturer's, Importer's, or Wholesaler's) — required for all classes, including Class A, and renewed annually. HSA assesses Good Distribution Practice for Medical Devices (GDPMDS) / QMS compliance before issuing.
• Registrant: foreign manufacturers must appoint a Singapore-based Registrant (ACRA-registered) who holds and controls the device registration; transfers require the current Registrant to relinquish.
• Product registration: Class A is exempt from registration but still needs a notification plus a dealer's licence; Class B–D require registration via evaluation routes (full, abridged, expedited, immediate).
• Dealer duties: report product defects and adverse effects, recall on HSA's instruction, keep distribution records, and carry out field safety corrective actions per HSA timelines.

Cross-market trap: because the Registrant controls the registration and transfers need consent, the Singapore Registrant relationship is a higher-stakes lock-in than the EU Authorized Representative.

Canada: The MDEL

Health Canada's establishment regime sits in Part 1 of the Medical Devices Regulations (SOR/98-282).

• Medical Device Establishment Licence (MDEL): required for importers, distributors (all classes), and Class I manufacturers. It is an establishment-level licence (not product approval), distinct from the product-level Medical Device Licence (MDL) for Class II–IV devices.
• Basis: issued by the Regulatory Operations and Enforcement Branch (ROEB) on attestation that documented procedures (complaint handling, recalls, mandatory problem reporting, distribution records) are in place; MDEL holders must demonstrate compliance on inspection.
• Exemptions: section 44 exempts retailers, healthcare facilities dispensing to patients, and certain others.
• Annual review: the MDEL must be renewed each year, with supplier information updates. Health Canada proposed amendments in November 2025 to refine importer/foreign-distributor relationships and supplier-information reporting.

Cross-market trap: a distributor outside Canada selling to a Canadian facility is treated as an importer/distributor requiring an MDEL — the obligation reaches across the border in a way the EU distributor rules do not.

Saudi Arabia: MDS-REQ 9

Saudi Arabia licenses every link of the chain through SFDA MDS-REQ 9 (Requirements for Licensing Medical Device Establishments, Version 2.0), administered through the GHAD system.

• Establishment licences cover manufacturers (MDMA), authorized representatives (MDAR), importers, and distributors.
• MDAR (Authorized Representative): required for any non-KSA manufacturer; the AR holds the Marketing Authorization and is the regulatory point of contact. Transferring an AR triggers a re-licensing sequence.
• Importer/distributor establishments: must hold the relevant licence, maintain documented procedures (storage, handling, traceability), and cooperate on post-market surveillance and recalls under MDS-REQ 11.
• Staffing: key roles require full-time Saudi nationals with defined qualifications.

Cross-market trap: Saudi Arabia layers two licences a foreign manufacturer must secure through a local party — the MDAR (representative licence) and the MDMA (product authorization) — plus establishment licensing for any in-KSA importer/distributor. None of the other four markets stacks representative-licensing on top of product authorization in the same way.

What to Verify in the Original Text

• EU MDR Articles 11(5), 13(2)–(7), 14(2), and 16 — confirm the importer's verification checklist, the distributor's sampling right, the Article 16 "becomes manufacturer" trigger, and the AR's joint liability.
• New Zealand Medicines (Database of Medical Devices) Regulations 2003, Regulations 5–10 and 14 — confirm the 30-day notification, the 10-day update rule, Schedule 1 exemptions, and the offence/fine provision.
• Singapore Health Products (Medical Devices) Regulations 2010 — confirm the dealer-licence categories, the Class A notification route, and the registrant-control/transfer rule.
• Canada SOR/98-282 Part 1, section 44 and GUI-0016 — confirm who needs an MDEL, the exemptions, and the attestation/inspection basis.
• Saudi MDS-REQ 9 v2 — confirm the MDMA/MDAR split, the GHAD application, and the staffing requirements.

Practical Implications for Supply-Chain Design

The five regimes reward different supply-chain structures. The EU demands an importer that performs per-shipment verification and registers in EUDAMED — so the importer role is operationally heavy, not just contractual. New Zealand lets you move fast but leaves safety responsibility entirely on the sponsor's reference-country dossier. Singapore and Canada both impose entity-level licensing that reaches across borders (Registrant control; foreign-distributor MDEL reach). Saudi Arabia is the only market that requires licensing the representative and the product and the importer/distributor establishments separately. When designing a single global distribution chain, map each jurisdiction's role assignments to your actual entities first — the same physical warehouse can be a "distributor" in the EU, an "importer" in Canada, and an "establishment" in Saudi Arabia, with a different licence for each.

Sources

• European Union, Regulation (EU) 2017/745 (MDR), Articles 11, 13, 14, 16 and 31: https://eur-lex.europa.eu/eli/reg/2017/745/oj ; European Commission, MDCG 2021-27 rev.1 — Q&A on Articles 13 & 14 (Authorised Representatives, Importers, Distributors): https://health.ec.europa.eu/system/files/2023-12/mdcg_2021-27_en.pdf
• New Zealand Medsafe, Regulatory Requirements for Medical Device Sponsors: https://www.medsafe.govt.nz/regulatory/DevicesNew/3-6RegulatoryRequirements.asp ; Medicines (Database of Medical Devices) Regulations 2003: https://www.legislation.govt.nz/regulation/public/2003/0325/latest/whole.html
• Singapore Health Sciences Authority, Health Products Act 2007: https://sso.agc.gov.sg/Act/HPA2007 ; Health Products (Medical Devices) Regulations 2010: https://sso.agc.gov.sg/SL/HPA2007-S436-2010
• Government of Canada, Medical Devices Regulations (SOR/98-282): https://laws-lois.justice.gc.ca/eng/regulations/SOR-98-282/ ; Health Canada, Medical Device Establishment Licensing (GUI-0016) and FAQ.
• Saudi Food and Drug Authority, MDS-REQ 9 — Requirements for Licensing Medical Device Establishments, Version 2.0: https://www.sfda.gov.sa/sites/default/files/2025-03/MDS-REQ%209_En_V2.pdf